|Bid||59.01 x 1300|
|Ask||59.35 x 1000|
|Day's Range||58.83 - 59.72|
|52 Week Range||45.76 - 68.34|
|Beta (5Y Monthly)||0.68|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov. 05, 2020|
|Forward Dividend & Yield||1.80 (3.03%)|
|Ex-Dividend Date||Oct. 01, 2020|
|1y Target Est||73.25|
Bristol Myers Squibb Co's cancer immunotherapy Opdivo in combination with Exelixis Inc's Cabometyx reduced the risk of death by 40% in previously untreated patients with advanced kidney cancer, according to data from a late-stage study to be presented on Saturday. The drug combination also doubled patients' median length of time before their cancer began to worsen to 16.6 months compared to progression-free survival of 8.3 months for patients treated with the chemotherapy sunitinib, an older Pfizer Inc drug sold under the brand name Sutent. "There is no doubt in my mind that this will be a major player" as an initial treatment for advanced kidney cancer, said lead researcher Dr. Toni Choueiri from Dana-Farber Cancer Institute in Boston.
Opdivo in Combination with CABOMETYX Demonstrates Significant Survival Benefits in Patients with Advanced Renal Cell Carcinoma....
Dr. Reddy's (RDY) settles litigation with Bristol Myers relating to patents for Revlimid (lenalidomide) capsules.